Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-04-12 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于公司发行股份及支付现金购买资产并募集配套资金暨关联交易事项获得中国证监会上市公司并购重组委员会审核通过暨公司股票复牌公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (568 characters) regarding the approval by the China Securities Regulatory Commission's M&A committee for the company's issuance of shares and cash to purchase assets and raise supporting funds, as well as the resumption of stock trading. It mentions that the formal approval document has not yet been received and that a further announcement will be made upon receipt. This is clearly an announcement about a capital raising and asset acquisition transaction, not the full transaction documents or detailed reports. The document is not a full financial report but an update on financing and capital structure changes. Therefore, it fits best under Capital/Financing Update (CAP).
2016-04-12 Chinese
关于收到药品审批意见通知件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (661 characters) from a company about receiving a regulatory notice from the National Medical Products Administration regarding a drug approval rejection. It does not contain financial data, management changes, or detailed reports. It is an official regulatory announcement about a drug approval decision, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2016-04-08 Chinese
关于持股5%以上股东部分股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a shareholder holding more than 5% of the company's shares. It details the number of shares pledged, the pledgee, and the purpose of the pledge. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a significant shareholder's share pledge, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or announcement of a report publication.
2016-04-07 Chinese
关于子公司收到药品补充申请批件的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary receiving drug approval certificates from a regulatory authority (国家食品药品监督管理总局 - National Medical Products Administration). It details the approval of drug supplements and the transfer of production technology. The document is short (845 characters) and does not contain financial data, financial statements, or detailed financial analysis. It is an announcement of a regulatory approval event related to product licensing, not a financial report or management update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing in the sense of officer certifications or compliance documents. The best fitting category is Regulatory Filings (RNS) as a general announcement of regulatory approval and company update that does not fit other specific categories.
2016-04-06 Chinese
独立董事关于第三届董事会第四会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a specific board meeting matter, referencing regulatory guidelines and company governance rules. It does not contain financial statements or detailed financial data but rather a formal opinion related to board decisions and compliance. The document length is short (716 characters), and it is clearly a governance-related statement rather than a full report or announcement of financial results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters.
2016-04-01 Chinese
国都证券股份有限公司关于公司使用暂时闲置自有资金和超募资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Guodu Securities, the sponsor institution, regarding the use of temporarily idle proprietary funds and over-raised funds by Fu'an Pharmaceutical (Group) Co., Ltd. for cash management. It includes specifics about the initial public offering, the amount of funds raised, usage of over-raised funds, management and control measures, investment plans, risk controls, and approvals by the board, supervisory committee, and independent directors. The document is a formal verification and review opinion on the company's cash management activities related to idle and over-raised funds, including compliance with regulatory requirements and internal approvals. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a standalone audit or verification report focusing on the use and management of funds, fitting the definition of an Audit Report / Information (AR). The document length (4611 characters) and content confirm it is a substantive report rather than a brief announcement or certification. Q1 2016
2016-04-01 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.